Q-omics provides the consensus-scored CCDC47 profile across patient tissues and cancer cell-line models. CCDC47 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCDC47 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, CCDC47 protein abundance shows 22,935 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, BLCA, and PDAC as cancer lineages where CCDC47 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC47 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC47 survival associations across molecular data types. CCDC47 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC47 RNA expression–survival associations across cancer types. High CCDC47 expression shows unfavorable associations in KIRP, CESC, KICH and LIHC, but favorable associations in KIRC and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CCDC47 RNA expression.
This table summarizes CCDC47 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC47. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC47 shows lower tumor expression in KICH and THCA and higher tumor expression in BLCA, HNSC, LIHC and STAD. The BLCA box plot shows higher CCDC47 RNA expression in tumor versus normal tissue (log2 FC = +0.942, t-test p < 0.001).
This table shows molecular features associated with CCDC47 in patient tissues and cancer cell lines. In patient samples, CCDC47 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC47 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
